Solid Biosciences (SLDB)
(Delayed Data from NSDQ)
$7.85 USD
-0.79 (-9.14%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $7.85 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Solid Biosciences Inc. (SLDB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$19.56 | $40.00 | $6.00 | 126.39% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Solid Biosciences Inc. comes to $19.56. The forecasts range from a low of $6.00 to a high of $40.00. The average price target represents an increase of 126.39% from the last closing price of $8.64.
Analyst Price Targets (9 )
Broker Rating
Solid Biosciences Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.20 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, 10 are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 90%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 9 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 1 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.20 | 1.40 | 1.40 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/24/2024 | SVB Securities | Joseph P Schwartz | Hold | Strong Buy |
5/31/2024 | Piper Sandler | Biren Amin | Not Available | Strong Buy |
3/28/2024 | William Blair | Timothy F Lugo | Not Available | Strong Buy |
3/18/2024 | Not Identified | Not Identified | Hold | Strong Buy |
3/15/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
3/15/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
3/11/2024 | H.C. Wainwright & Co. | Arthur He | Strong Buy | Strong Buy |
3/1/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
11/23/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 10 |
Average Target Price | $19.56 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 91 of 253 |
Current Quarter EPS Est: | -0.68 |